Patient Stories
LDL-C: The Overlooked Risk
- For very high-risk ASCVD patients, guidelines are clear — target LDL-C <55 mg/dL with ≥50% reduction from baseline.1
- Every mmol/L reduction lowers CV risk. Don’t let LDL-C be the missing link in secondary prevention.1
Through this patient journey, we illustrate the gap in LDL-C management and the evidence-based treatment approach needed to reach targets and reduce cardiovascular risk
EDA Approval No: WF0424OA5708/042026 EDA Invalidation Date:06/04/2027
References
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2020 Jan 1;41(1):111-88.. Available at: https://academic.oup.com/eurheartj/article/41/1/111/5556353 . Last accessed:16/09/2025.
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |